Abbvie $ABBV is heading to $100 after a BREAKOUT. Today, the FDA accepted its SBLA for Botox for the treatment of pediatric patients with neurogenic detrusor (bladder muscle) overactivity. This is not a BUY/SELL recommendation. $XLV $XPH $IYH #SP500 $SPY $SPX https://t.co/2mh99u5rer